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Background: Acute kidney injury (AKI) is a frequent condition in hospitalised patients undergoing major surgery or
the critically ill and is associated with increased mortality. Based on the volume of the published literature
addressing this condition, reporting both supporting as well as conflicting molecular evidence, it is apparent that a
comprehensive analysis strategy is required to understand and fully delineate molecular events and pathways
which can be used to describe disease induction and progression as well as lead to a more targeted approach in
intervention therapies.
Results: We used a Systems Biology approach coupled with a de-novo high-resolution proteomic analysis of kidney
cortex samples from a mouse model of folic acid-induced AKI (12 animals in total) and show comprehensive mapping
of signalling cascades, gene activation events and metabolite interference by mapping high-resolution proteomic
datasets onto a de-novo hypothesis-free dataspace. The findings support the involvement of the glutamatergic
signalling system in AKI, induced by over-activation of the N-methyl-D-aspartate (NMDA)-receptor leading to
apoptosis and necrosis by Ca2+-influx, calpain and caspase activation, and co-occurring reactive oxygen species
(ROS) production to DNA fragmentation and NAD-rundown. The specific over-activation of the NMDA receptor
may be triggered by the p53-induced protein kinase Dapk1, which is a known non-reversible cell death inducer
in a neurological context. The pathway mapping is consistent with the involvement of the Renin-Angiotensin
Aldosterone System (RAAS), corticoid and TNFα signalling, leading to ROS production and gene activation through
NFκB, PPARγ, SMAD and HIF1α trans-activation, as well as p53 signalling cascade activation. Key elements of the
RAAS-glutamatergic axis were assembled as a novel hypothetical pathway and validated by immunohistochemistry.
Conclusions: This study shows to our knowledge for the first time in a molecular signal transduction pathway map
how AKI is induced, progresses through specific signalling cascades that may lead to end-effects such as apoptosis
and necrosis by uncoupling of the NMDA receptor. Our results can potentially pave the way for a
targeted pharmacological intervention in disease progression or induction.
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A number of tightly controlled and complex processes are
performed by heterogeneous cell populations of the kid-
ney, including blood filtration by microvascular endothe-
lial cells and podocytes and secretion and re-absorption
by proximal tubular epithelial cells. Acute kidney injury
(AKI) is a frequent clinical event associated with a rapid
loss of kidney function, leading to high morbidity and
mortality [1] in up to 22% of hospitalised patients [2].
However, it is estimated that one-fifth of AKI that occurs
after hospital admission is predictable and avoidable [3].
In light of the economic burden of 0.4% to 0.6% of the
total healthcare costs, corresponding to £400 m - £600 m,
annually spent on treatment for acute kidney injury in the
UK alone [4], a clear need for development of means to
predict and/or early detect and prevent/treat AKI arises.
It has been by now widely accepted that AKI represents
a continuum or spectrum of diseases that could be identi-
fied at an early stage, rather than the previous terminology
of acute renal failure describing an “all or nothing” condi-
tion [5]. The recognition of renal impairment at an early
stage would allow for an immediate course of action to al-
leviate symptoms and disrupt the process of functional
decline [6], however this implies that this condition is
comprehensively understood on a molecular level to allow
for targeted intervention therapies.
AKI can be caused by many different events such as
ischemia, vasoconstrictive drugs, exposure to toxins,
hypotension linked to sepsis, and obstruction of the urin-
ary tract, and leads to a number of complications, inclu-
ding metabolic acidosis, high potassium levels, uremia,
changes in body fluid balance, and damage to and failure
of other organs [7]. Molecular hallmarks of AKI are accu-
mulation of free and esterified cholesterol, inflammation
and inflammatory response, altered tubule dynamics lead-
ing to increased luminal sodium, hypoxia, cellular ATP
depletion, renal cell apoptosis and necrosis, and hypergly-
caemia, which is also a contributor to AKI (see Table 1).
The factors causing AKI and their interaction with each
other are still incompletely understood, which is surpris-
ing in light of the vast amount of scientific reports in this
area. However, a systematic and in-depth mining of the
literature, as employed by a comprehensive Systems
Biology approach, coupled with high-resolution mass
spectrometry analysis of diseased tissue could pave the
way forward. Systems Biology, or integrative biology, uses
descriptive terms to understand complex interactions
based on the analysis of network behaviour and dynamic
aspects. Here, we demonstrate a comprehensive analysis
of AKI induced in a mouse model system to investigate
and identify key signalling cascades, inferred metabolic
alterations and molecules modulated in this highly
complex and clinically relevant disease. Nevertheless it
should be noted that animal models of AKI might notreflect this clinically critical condition observed in man,
where an unobserved laps of mere hours between onset
and catastrophic irreparable kidney failure can mean life
or death. An acceptable approximation is the model
chosen here, where an single overdose of folic acid causes
the same end-effect of kidney damage observed in clinically
manifested AKI.
Results
We first established a high-resolution proteomic map of
protein expression profiles using 6 sham injected controls
and 6 folic acid overdosed mice. Folic acid nephropathy is
a well established murine model of AKI using a single in-
traperitoneal injection overdose of folic acid and harvest-
ing of kidneys after 24 hours [8]. Kidney cortex proteins
were extracted, trypsin-digested, and analysed by high-
resolution liquid chromatography mass spectrometry
(LC-MS/MS). After merging the individual independent
mass-spectrometric analyses, 6564 non-redundant pro-
teins were detected (Additional file 1: Table S1, and de-
tailed information of data processing can be found in
Additional file 2). 14 of these proteins were detected only
in control samples, 1050 only in AKI, and 5500 in both
sets of conditions. Statistical testing using Mann–Whitney
showed that 2521 proteins were statistically significant
(p-values <0.05), and when also taking fold-change cal-
culations into considerations then the dataset indica-
ted 1480 molecules to be significantly changed in AKI
(p-values <0.05 and fold changes >2). 420 of these proteins
were found in both control and AKI samples, 14 only in
controls, and 1046 molecules only in AKI samples. After
initial database matching and employing gene ontology
clustering to assess data quality and overlapping character-
istics, the data were mapped onto existing general pathway
maps to identify affected cascades and modulatory events.
More than 50 signalling cascades (see Additional file 2),
mainly due to overlapping features in the existing maps,
were initially identified to be of interest in further down-
stream analysis based on their potential functional re-
levance. In parallel, we assembled potential pathway
maps derived from the pertinent AKI-focussed literature.
Through a manual iterative feedback analysis and deep-
mining of inferred and prior knowledge (Figure 1),
extending the pathway analysis beyond the reported AKI-
signalling cascades, and molecule-by-molecule pathway
delineation and manual feature look-up, we assembled
plausible signalling cascades which led to a combined path-
way map (Additional file 3: Figure S1). The same approach
was also used to map the metabolic pathways modulated
in AKI, as well as probable gene activation cascades based
on reported modulation of transcription factors such as
NFκB, which were integrated into the AKI model.
Key pathways which were previously reported to be main
events in AKI induction, such as the Renin-Angiotensin
Table 1 Hallmarks and causes defining AKI
Event Modulated associated event Modulation in AKI Molecular cause
RAAS activation Angiotensin signalling up Cathepsin/kallikrein/kininogen activity, blood pressure, pH
Vasoconstriction Vasoconstrictors (endothelin,
angiotensin, MMP2)
up RAAS pathway induction, endothelial obstruction
Vasodilators (NO) down NOS inhibition, reduced NO bioavailability by ROS activity
Hyperglycaemia up 20-hydroxyeicosatetraenoic acid (20-HETE), Glycogen
phosphorylase, PPARγ
Elevated blood pressure Hypertension up Renin, 20-hydroxyeicosatetraenoic acid (20-HETE),
mineralocorticoid receptor
Hypoxia HIF1α up Induction by vasoconstriction and ECM accumulation
NADPH oxidases up Induction by RAAS and PLCβ
ROS levels up NAD(P)H oxidases, P450 isoforms, Xanthine dehydrogenase
NFκB activity up ROS-modulated activation
Inflammation factors (TNFα, TF,
PAT1, MCP1)
up NFκB-mediated gene expression
Inflammation and
inflammatory response
up JAK/STAT- and NFκB-dependent gene activation, other
pathways
Atherogenesis, fibrinogenesis up TGFβ signalling and gene activation pathway
ATP levels down Depletion by PMCA activity and others, and inhibition of
de-novo ATP production
NAD levels down Rundown by PARP
Hypoxanthine levels up Metabolic shift from accumulated XMP, IMP and Inosine
Necrosis up ROS, SOD, OH., DNA damage, PARP, NAD rundown
PI3K modulation PI3Kinase activity down Inhibition by Jnk and PKCα
Insulin signalling down Inhibition by RAAS and PPARγ systems
Accumulation of free and
esterified cholesterol
Systemic stress response up LIPE inhibition by PP1
Na+/Cl- retention, increased
luminal Na+
Aldosterone/cortisol signalling
events
up Mineralocorticoid/Glucocorticoid-receptors, acting on
Na+/Cl- pumps
Ras activation Ras signalling up Mineralocorticoid/Glucocorticoid-receptor-dependent gene
activation, Angiotensin receptor signalling
Cytoskeletal reorganization ECM remodelling up Hsp27, ATP depletion, Rac1 activation, Ras mediated events
Tubular cell dynamics Infiltration of immature cells up Pro-apoptotic signals
Clinical and disease model observations were analysed based on modulated associated events, directionality in terms of in- or decrease, and plausible
molecular causes.
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TNFα-signalling cascade, could be confirmed in our
analysis to be up-regulated. Upstream activators, such
as the kallikrein and cathepsin systems, were also in-
duced, suggesting a specific activation of the aforemen-
tioned RAAS axis. Additional up-regulated modulatory
events, which were per se not associated with the cur-
rently perceived molecular model of AKI are the gluta-
matergic signalling cascades and associated calcium-flux
pathways, which have a major detrimental effect on both
apoptosis and necrosis. A substantial amount of infor-
mation is available about glutamate-dependent pathways
and signalling events in a non-renal, specifically neuro-
logical context, and it was surprising to encounter a consid-
erable level of glutamatergic pathway elements associated
with renal dysfunction. The specific involvement underphysiological conditions of ionotropic as well as metab-
otropic glutamate receptors in kidney is currently un-
known, however a dysfunction, such as over-stimulation
and –activation is expected to lead to the same effects
observed in other systems, e.g. uncontrollable calcium-
influx and ultimately cell death. This observation is fur-
ther acerbated by an apparent simultaneous induction
of the calcium-flux machinery, involving the calcium-
import and –export channels, such as calcium pumps
(SERCA and PMCA) as well as ryanodine receptors
and calcium-sensitive modulators. A potential assembly of
signalling events originating from the RAAS axis and
involving the most prominent glutamate-sensitive calcium-
channel NMDA receptor is depicted in Figure 2B. As
shown, signalling from the renin-induced angiotensin
receptor leads to a cascade of known signalling and
Figure 1 Workflow of AKI sample analysis. Systems Biology approaches require prior knowledge and/or inferred pathways from independent
sources used to map measured data (top). In this work these sources include an extensive novel proteomic dataset, and that has undergone
rigorous statistical analysis. The predicted affected pathways are then mapped further by extensive manual literature mining and delineation to
establish plausible cascades and pathway maps, followed by integration of all data to assemble a final model. Re-iterations between each and all
steps between pathway mapping and model assembly ensure a best-fit model for both the de-novo data as well as prior knowledge.
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p38kinase, MSK and activation of the transcription factor
SP1. The latter promotes gene activation of the NMDA
receptor GRIN1 which however is also dependent on SP3
inhibition. SP3 inhibition can be induced by oxidative
stress, reflected in this scheme in the stimulation of
NADPH oxidase NOX, predicted to result from the acti-
vation of the up-stream kinase PKCα. Oxidative stress
also stimulates the death-associated protein kinase Dapk1,
which can target the NMDA receptor and leads to a
permanent-open state of the channel, allowing calcifica-
tion of the intracellular environment. This in turn triggers
the mitochondrial- as well as nuclear-based apoptotic and
necrotic molecular machinery.
To enhance these hypotheses and predictions, we vali-
dated specific key elements in this delineated pathway
by immunohistochemistry, as shown in Figure 2A. We
also tested whether the potentially anti-apoptotic protein
Hsp27 is regulated according to the MS-results. This
protein is involved in cytoskeletal remodelling, which
might also be an involvement of the NMDA receptor
under physiological conditions, however based on our
pathway model this would imply that apoptosis is to
some extent inhibited, whereas necrosis is not. All of the
proteins tested, namely PLC2β, Ras, MSK, Grin1, Dapk1
and Hsp27, could be confirmed to be up-regulated,
as measured by the proteomic mass-spectrometry ap-
proach, thereby further emphasizing the importance of
this downstream pathway in the development of the AKI
phenotype. Unsurprisingly we could not detect any indi-
cation of the involvement of the insulin pathway, either
up- or down-stream of the insulin receptor, but insteadobserved an up-regulation of known inhibitors of
insulin-signalling such as Socs3 and Ptprf.
Additionally, our analysis of the glycolysis and glyco-
genolysis pathways, which are modulatory targets of
insulin-signalling, shows a significant up-regulation of
enzymes involved in glucose and fructose release, and
no indication of an equally activated down-stream me-
tabolism from Fructose-1,6-bisphosphate to pyruvate or
lactate. This suggests an accumulation of Fructose-1,6-
bisphosphate, which is a known allosteric inhibitor of
Adss, an enzyme in the de novo pathway of AMP pro-
duction. This inhibition would lead to an accumula-
tion of IMP, and in conjunction with the observed
up-regulation of 5′(3′)-deoxyribonucleotidase Nt5c, to
inosine and ultimately hypoxanthine and xanthine build-
up. Those last two stages are a characteristic hallmark of
AKI, thereby explaining the previously described obser-
vations of an accumulation of the latter two chemical
compounds on a molecular level (see Table 1).
Discussion
AKI has a major impact on survival in hospitalised pa-
tients undergoing extensive surgery [9], and a large
number of studies have been undertaken to understand
the molecular causes leading to and being involved in
this complex disease [10,11]. Here, we employed a non-
biased systematic approach using a combination of
Systems Biology, proteomics and de-novo pathway mapping
and immunohistochemical validation to elucidate major
pathways and signalling cascades in order to contextualise
previous findings and uncover novel potential targets for
pharmacological intervention. The analysis focuses mainly
Figure 2 Immunohistochemistry and pathway analysis of AKI modulated pathways along the RAAS/glutamatergic axes. (A) Molecules
of interest found and/or predicted to be differentially expressed based on the proteomics data and subsequent pathway analysis, were verified
by immunohistochemistry of kidney tissue. (B) These proteins were delineated into specific signalling cascade involving the angiotensin to
p38kinase downstream signalling and NMDA-R1 (Grin1) pathway. All six molecules tested (highlighted in red) showed an up-regulation as
measured by mass spectrometry experimentation in AKI samples and potentially validates the proposed signalling cascade. Original magnification
of immunohistochemical microscopy is ×20 (MSK and hRas control ×40 in order to observe the intense nuclear staining of kidney epithelial cells),
black bars in the panels are 10 or 20 micron as indicated.
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the known hallmarks using the folic acid-overdose animal
model and can be regarded as a first attempt to describe
this condition in a molecular mechanistic way.
An initial finding of this mapping effort was the appa-
rent complexity of AKI and associated pathways, where
a plethora of signalling cascades appears to be modu-
lated simultaneously. This could be due to many kidney
cell types being in an active state of inflammation signal-
ling, apoptosis induction, stress, and other modulatory
events, as also supported by the literature [12]. As many
cascades can be activated in more than one way, and in-
duction of AKI can occur via multiple stimulation or
entry points [13], it appears plausible that these path-
ways are merging to similar down-stream targets leading
to the observed deleterious events in kidney injury.Our analysis revealed that a major pathway involved in
AKI is the RAAS axis, which has been reported multiple
times before [14,15], further confirming the validity of
the approach. Renin activation can occur in several ways,
either by kallikrein, cathepsin or other stimuli as indi-
cated in Additional file 3: Figure S1. Many of those acti-
vating proteins were markedly up-regulated in AKI.
A further main crucial initiation step leading towards
AKI is based on up-stream activation via TNFα, where in-
hibition of this molecule prevents apoptotic cell death
[16]. Mapping of modulated proteins found in this study
clearly indicates the involvement of this cascade in AKI.
TNF signals via Jnk to inhibit phosphoinositide 3-kinases
(PI3Ks), which in turn leads to the release of cathepsin B-
containing lysosomes and to renin activation [17], as well
as activation of the pro-apoptotic protein p53 [18]. TNFα
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shown in Figure 3. Mounting evidence suggests that the
RAAS plays a major role in kidney injury and inflamma-
tory processes [19], whereas TNFα and TNF-like cyto-
kines are involved in induction of cellular responses such
as inflammation as well as induction and progression of
apoptotic cell death [20].
Along these lines, the data obtained also suggest up-
regulation of inflammatory pathways, indicated in our
analysis to involve activation by the RAAS axis through
the NFκB pathway, leading to downstream signalling by
interleukins (see Figure 3). These results are supported by
an observed role for TLRs in promoting inflammation
and tissue injury in AKI, which synchronise their inflam-
matory signal activations via NFκB [21]. The activation of
the RAAS axis also leads to the activation of a number of
transcription factors [22], and our results indicate geneFigure 3 Global molecular axes invoked during AKI. Many interactions
pathophysiology of AKI. These interactions are bidirectional between the c
Inflammatory mediators released from proximal tubular cells influence end
of cell adhesion molecules) that in turn interfere with and modulate endot
hypoxia within the local environment. Co-occurring augmented ROS produ
events leading to oxidative stress. The impairment to replenish the intracel
one of the major contributors to cell injury and tissue damage. Primary pat
activation cascades (blue arrows), signalling events (black arrows and inhib
Modulations are indicated as arrows (positive signalling events) or t-bars (in
Pharmacological intervention studies in inhibiting AKI or alleviate AKI-depe
inhibition of targets (red circles) or stimulation (green triangles).activation cascades involving among others NFκB, PPARγ,
SMAD and HIF1α.
The significant changes in levels of e.g. collagens, Ena/
VASP, Hsp27/Hspb1 and proteases such as MMP2 were
interpreted by the bioinformatic tools to be correlated with
cytoskeletal remodelling, extracellular matrix (ECM) deg-
radation, and associated cell detachment, all linked to kid-
ney injury [23]. The cytoskeletal reorganisation by Hsp27
has been shown to inhibit fibrogenesis in obstructive ne-
phropathy [24].
The marked up-regulation of the molecular clusters asso-
ciated with apoptotic pathways, including NADPH oxidases
(NOX) and P450 monooxygenases, nitric oxide synthase
Nos1, calpains Capn3 and 11, caspase Casp8, poly-[ADP-ri-
bose]-polymerase Parp3, 6, and 12 and Serine-protein ki-
nase ATM, indicates activated cell-death cascades linked to
prolonged hypoxia. Vasoconstriction, one of the hallmarksexist between endothelial cells, epithelial cells, and blood cells in the
ells involved, and result in specific functional and structural alterations.
othelial cell processes (e.g. increased vasoconstriction and expression
helial cells, leading to reduced microvascular flow and continued
ction within the cells and cross-signalling induces additional signalling
lular ATP pool, as well as NAD depletion, of vascular and tubular cells is
hways which are involved in multifaceted AKI are delineated in gene
itions) and metabolic pathways (green arrows and inhibitions).
hibitions). Ultimate clinically observed end-points are marked in bold.
ndent symptoms by targeting specific molecules are indicated by
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several proteins such as NOX and P450 monooxygenases
and leads to ROS generation, including superoxide and
hydrogen peroxide production by xanthine oxidase as a re-
sult of metabolic hypoxanthine accumulation [25]. This
is acerbated by the notion that kidney injury can also in-
duce the over-production of nitric oxide (NO), which, with
superoxide, forms peroxynitrite, and causes cell damage via
DNA fragmentation [26]. Over-production of ROS is linked
to the induction of apoptosis and necrosis, and a number
of pro-apoptotic and necrotic pathways have been shown
to exist, some of which also require the activation of the
mitochondrial calpain system through sustained Ca2+-
influx [27]. The classical apoptotic pathway involves the
release of mitochondrial proteins, leading ultimately to acti-
vation of caspases [26]. Regulated necrosis also contributes
to cell loss [28] (Figure 3, Additional file 3: Figure S1 and
Table 1).
A major novel finding is the modulation of proteins in-
volved in glutamatergic signalling. This is exemplified by
the up-regulation of key components of the glutamate re-
sponse system, such as the metabotropic glutamate recep-
tor Grm1 (also known as mGluR1), and ionotropic
glutamate receptors Grin1 (NMDA receptor NR1), Gria2
(AMPA receptor GluR2), and specific scaffolders of these
receptors, as well as known down-stream signalling mole-
cules (e.g. CamK2b, PP2B, and Nos1) (Additional file 3:
Figure S1). Activation of glutamatergic signalling compo-
nents is one possible route to activate Ca2+-flux pathways
[29]. Podocytes and tubular cells express glutamate recep-
tors [30] including functional Grin1 NMDA receptors
[31], raising the possibility that neuron-like signalling con-
tributes to glomerular function [32]. Glutamatergic signal-
ling driven by podocytes contributes to the integrity of the
glomerular filtration barrier and may regulate glomerular
filtration [33]. Additionally, one of the metabotropic glu-
tamate receptors, Grm1, is expressed in glomerular po-
docytes [34]. Although the stimulus for increased NMDA
receptor expression in AKI has not been characterised,
hypoxia is known to induce the transcription of glu-
tamatergic signalling components such as the NMDA
receptors in non-renal cells through inhibition of the tran-
scription factor SP3. SP3 inhibits transcription by occupy-
ing the genomic translation initiation site, and activation
of SP1 which in turn occupies the freed site and promotes
the transcription of target genes [35].
Collectively, based on the presented data, we could
hypothesize that excessive activation or sustained acti-
vation of NMDA receptors in tubular cells or podocytes
promotes oxidative stress, mobilization of cation channels,
disproportionate Ca2+ influx and overloading, excessive
ROS generation, and apoptotic cell death [36] similar to
what was shown to occur in the neurological environment
[37]. Indeed tissue glutamate is high in AKI [38] andpharmacologically blocking this receptor with D-AP5,
a synthetic glutamate analogue which binds to the
glutamate-binding site of the NMDA receptor and sup-
presses pore opening, prevented tissue injury [39]. Shown
in Additional file 3: Figure S1 are proteins and signalling
events, assembled to depict probable cascades driving
both, apoptosis and necrosis in kidney tissue after injury.
The glutamate receptor Grin1/NMDA-R1, which is re-
sponsible for cellular Ca2+-overload leading to irreversible
caspase activation and apoptosis, in conjunction with sus-
tained ROS production, and ultimately energy-depletion
and necrosis, may be a major contributor to these events.
Dapk1, a gene activation target of p53, can mediate the
pro-apoptotic activity of TNFα by inhibition of NFκB sig-
nalling [40]. Additionally, the NMDA receptor is a known
target of Dapk1, where Dapk1-mediated channel modu-
lation results in a permanently open NMDA receptor,
leading to cell death [41]. Remarkably, we also observed
an orchestrated up-regulation of relevant scaffolders
(Homer1/3, Dlg1, and Dlgap4) which link the glutamate
receptors directly to downstream signalling cascades ran-
ging from Ca2+-signalling to phospholipase and adenylate
cyclase cascades and interlinking pathways. This further
supports the importance of these receptors in AKI.
Other Ca2+ channels, which we observed to be up-
regulated in AKI, and that could potentially contribute to
Ca2+-overload are Ca2+-import channels such as voltage-
sensitive calcium channels VSCC (isoforms Cacna1g/h and
Cacnb1) and transient receptor potential channels TRP
(isoforms Trpc4, Trpm1/3), intracellular release channels
sarcoplasmic/endoplasmic reticulum calcium ATPases
SRCA (isoforms Atp2a1/2) which are dependent on ATP
hydrolysis, and others (Slc8a3, Ryr1). Simultaneously we
also detected up-regulation of Ca2+-efflux channels plasma
membrane calcium-transporting ATPases PMCA (isoforms
Atp2b1/2/3), which are dependent on available ATP to
function. The depletion of intracellular ATP pools could
therefore lead to an asymmetric Ca2+-flux and exacerbate
the intracellular calcification even further.
We also extracted supportive information from the li-
terature, where pharmacological or other intervention
studies reported modulatory effects on kidney injury. The
results are summarised in Additional file 4: Table S2, and
also indicated in Figure 3. Inhibition of molecules down-
stream of TNFα and involved in ROS production and
hyperglycaemia, as well as specific activation of NFκB cas-
cades, all had an improving or attenuated outcome on
AKI prevention. Of particular interest is the inhibition of
TNFα signalling by using TNFα antibodies which resulted
in prevention of AKI [16]. Inhibition of glutamate signal-
ling via the NMDA receptor, by using the channel blocker
D-AP5, has been shown to significantly reduce ischemia/
reperfusion injury (I/RI) -induced glomerular and tubular
dysfunction [39], and NMDA-induced injury, which leads
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reduced by using calcium antagonists nimodipine and
dantrolene in an animal model of retinal injury [42].
Nimodipine targets and blocks L-type calcium channels,
whereas dantrolene inhibits ryanodine receptors. Nimo-
dipine was shown to alleviate tubular cell necrosis in
transplantation-induced AKI [43]. Dantrolene in par-
ticular gained interest as it was shown to be beneficial
in protecting against I/RI in animal models of heart-,
brain- and potentially liver-induced I/RI [44]. However,
dantrolene was shown to be ineffective in protecting renal
function [45]. The same study investigated two other
calcium-channel inhibitors, namely nicardipine, which
blocks L-type calcium channels such as CACNB1, and
TMB-8, blocking inositol 1,4,5-trisphosphate receptors.
They could demonstrate that both compounds applied in
pre-conditioning prior to I/RI had a positive effect bothFigure 4 Clustered view of pathways involved in AKI. A summarised ov
apoptosis and necrosis is shown. Based on the bioinformatics approach the
and cell death appear to be key targets for therapeutic intervention. Of the
concentrate in selective ROS targeting. In this respect recent successful atte
evidence that targeting cell death and NFκB might be beneficial, although
selective approaches. By contrast the role of glutamatergic signalling in AK
activating the RAAS axis, though it is known that different AKI-conditions c
events depicted. Since pathway names can be ambiguous, the proteins inv
listed as well. The protein coloration ranges from green (down-regulated) t
transcriptional and translational events.in vitro on tubular cells by decreasing the apoptotic effect,
and in vivo in a rat renal model in kidney functional integ-
rity. The results of those pharmacological studies listed in
Additional file 4: Table S2 suggest that AKI in principle
can be prevented or its effect diminished, and a combi-
nation of various drugs, targeting specific AKI-induced
pathways and molecules, could be a way forward in di-
sease prevention or therapeutic intervention.
Conclusions
A potential synopsis of pathways and signalling events
evoked during AKI leading to Ca2+-overload and apoptosis
as well as necrosis is shown in Figure 4, and a focus centred
around the NMDA receptor is shown in Figure 2B. The
relevant endogenous NMDA receptor ligand in AKI has
not been characterised, however kidney glutamate levels
are increased in AKI [38]. To further substantiate thiserview of signalling cascades triggered by AKI leading ultimately to
Angiotensin-Aldosterone system, ROS, NFκB, glutamatergic signalling
se, ROS targeting approaches have failed to date and efforts should
mpts have focused on mitochondrial ROS targeting. There is also
the complexity of the NFκB system requires exploration of more
I remains largely unexplored. The initial entry-point was selected by
an have other starting points within and outside the sequence of
olved and found in the most significant dataset of 1480 entries are
o red (up-regulated). Pathway names in green are evoked after
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involved in this axis as by immunohistochemistry shown
in Figure 2A. The signalling cascade downstream of
angiotensin-receptor 1 activates PLC2β which signals to
PKCα. Both these proteins were up-regulated in AKI based
on the mass-spectrometric analysis and confirmed for
PLC2β by immunohistochemistry. PKCα activation leads to
ROS production via NOX [46], and induces gene activation
of the NMDA receptor, which we found to be up-regulated
by both techniques used. This gene induction step also
requires activation of MSK, which we also found to be up-
regulated. Additionally, we could show that Hsp27 is up-
regulated, indicative of cytoskeletal reorganisation, and we
could demonstrate that Dapk1 is also up-regulated. Hsp27
up-regulation may protect from angiotensin II- and high-
glucose-induced apoptosis [47]. All these events are poten-
tially linked to both apoptosis and necrosis, and through
this up-regulated pathway could be demonstrating a prob-
able route of tubular epithelial fate in AKI.
The tissue proteomics approach identified here may
eventually be optimized for its use in diagnostic/sta-
ging clinical pathology and the molecular fingerprint
identified may be used to explore different molecular
types of clinical AKI that may require different thera-
peutic approaches.
In summary we assembled a global pathway model for
AKI based on proteomic changes, and further support the
concept that the approach of in-depth Systems Biology
coupled with high-resolution proteomic analysis repre-
sents a valuable approach to elucidate complex pathways
and systems, especially in multifaceted diseases such as
AKI. This combined methodology can be applied to
search for druggable targets and identify key nodes where
molecular/pharmacological interventions are most likely
to have an impact on the system as a whole, as well as
predictions for disease biomarkers. One such target could
be the glutamatergic system, however the NMDA recep-
tor itself might not be an ideal lead due to its involvement
in neurotransmission in other areas like cardiac function,
but a renally localised combinatorial pharmacological
intervention, blocking both glutamatergic signalling and
Ca2+-flux could be of beneficial effect.
Methods
Animal model
Folic acid nephropathy is a classical model of AKI [48].
C57/BL6 mice from IFFA-CREDO (Barcelona, Spain) (12-
to 14-week-old) received a single i.p. injection of folic acid
(Sigma) 250 mg/kg in 0.3 mol/L sodium bicarbonate (AKI
animals) or vehicle alone (controls) and mice were killed
24 h later [8]. Kidneys were cold saline perfused in situ
before removal. One kidney from each mouse was fixed in
buffered formalin, embedded in paraffin and stained with
hematoxylin-eosin or used for immunohistochemistry.The kidney cortex from other kidney was snap-frozen in
liquid nitrogen for protein studies. The study was ap-
proved by the IIS-FJD animal ethics committee and
followed Directive 2010/63/EU on the protection of ani-
mals used for scientific purposes.
Sample preparation
Tissue samples were weighed out and extracted using the
Filter Aided Sample Preparation (FASP) method [49].
Briefly, tissue samples were homogenised in SDS-lysis
buffer (1:10 sample to buffer ratio) (0.1 M Tris–HCl
pH 7.6 supplemented with 4% SDS and 0.1 M DTT) using
an Ultra-Turrax T 25 (IKA, Staufen, Germany), incubated
at 95°C for 3 minutes and clarified by centrifugation at
16,000 g for 5 min at room temperature. An aliquot of the
supernatant was taken and placed in a Micron YM-30 fil-
ter device (Millipore, Watford UK). 8 M Urea buffer (UA)
was added to the protein extract and then centrifuged at
14,000 g for 15 minutes. This step was repeated twice
after which the protein extract was mixed gently for 1 mi-
nute with 0.05 M iodoacetamide buffer (IAA) and incu-
bated for a further 20 minutes prior to centrifugation. UA
buffer was again added and centrifuged (twice). Ammo-
nium bicarbonate buffer (50 mM of NH4HCO3, pH 8)
(ABC) was then added and centrifuged (twice) before in-
cubating overnight with trypsin. The trypsin homogenate
was centrifuged and washed with ABC buffer prior to
acidification with 10% formic acid. Sample volumes were
adjusted to match final concentration of protein prior to
analysis by LC-MS/MS.
LC-MS/MS mass spectrometry analysis
Tissue extracts were separated on a Dionex Ultimate 3000
RSLS nano flow system (Dionex, Camberly UK). A 5 μl
sample was loaded in 0.1% formic acid and acetonitrile
(98:2) onto a Dionex 100 μm × 2 cm, 5 μm C18 nano trap
column at a flowrate of 5 μl/min. Elution was performed
on an Acclaim PepMap C18 nano column 75 μm × 50 cm,
2 μm, 100 Å with a linear gradient of solvent A, 0.1%
formic acid and acetonitrile (98:2) against solvent B, 0.1%
formic acid and acetonitrile (20:80) starting at 1% B for
5 minutes rising to 30% at 400 minutes then to 50%B at
480 minutes. The sample was ionized in positive ion mode
using a Proxeon nano spray ESI source (Thermo Fisher
Hemel UK) and analyzed in an Orbitrap Velos FTMS
(Thermo Finnigan, Bremen, Germany). The MS was oper-
ated in a data-dependent mode (top 40) to switch between
MS and MS/MS acquisition and parent ions were frag-
mented by collision-induced dissociation (CID). Data files
were searched against the IPI mouse non-redundant data-
base (version 3.8.5) using SEQUEST with enzyme specified
as trypsin. A fixed modification of carbamidomethylation
was set and oxidation of methionine and proline as va-
riable modifications were selected. Mass error windows of
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spectively. In SEQUEST, only peptides that showed mass
deviation of less than 10 ppm were passed, the peptide
data were extracted using high peptide confidence and top
one peptide rank filters. Statistical p-value analysis was per-
formed using the Mann Whitney test (implemented in in-
house software). Normalisation of the mass spectrometry
data was done using Histone H2B. Similar results were ob-
tained when the normalisation was performed against actin
(skeletal muscle isoform).
Systems Biology analysis
Data merging was done by Blast-searching the SwissProt
database with all 9930 identified molecules individually,
or by batch-transfer using the UniProt online tool, to
transfer all IPI accession numbers to the SwissProt identi-
fiers, followed by combining all duplicated entries. Mass
spectrometry measurement values were adjusted using
the average or, in case where the protein was only found
in one instance in a sample, by taking only the measured
value. This dataset of 6564 entries was then used in the
downstream analysis (Additional file 1: Table S1). The p-
values were re-calculated using the Mann Whitney test,
and the fold changes calculated by using the averages
where missing values were ignored. 1480 molecules were
significantly changed in AKI using high-stringency cut-off
values of p-values <0.05 and fold changes >2. Of those,
1046 were only found in the AKI kidney samples, 14 only
in controls, and 420 in both. Gene ontology analysis was
performed using the CytoScape plug-in ClueGO. Initial
pathway mapping was done using KEGG (online) as well
as WikiPathway maps (using PathVisio software), where
28 partially overlapping metabolic and signalling cascades
could be identified. Data for molecular properties were
obtained from UniProt and the published literature, as
well as other databases (PADB, BRENDA, Reactome,
IntAct, GeneCards, NCBI RefSeq and Entrez). De-novo
pathway maps were constructed by extended manual
literature searches. Gene activation cascades were put
together by manual literature mining and use of on-line
resources such as GeneCards. AKI-specific metabolic
maps were created based on information from KEGG,
Reactome, BRENDA and UniProt, as well as the published
literature. The delineated pathways were then combined
into plausible signalling cascades and initial sub-models
were manually assembled using the PathVisio software. A
final model was established after several re-iterations and
literature cross-checks.
Immunohistochemistry
Immunohistochemistry was carried out in 5 μm thick
paraffin-embedded tissue sections [50]. The primary anti-
bodies were rabbit polyclonal anti-PLCβ2, goat polyclonal
anti-HSP27, rat monoclonal anti-H-Ras, rabbit polyclonalanti-MSK1 (1:100, Santa Cruz biotechnology), rabbit poly-
clonal anti-NMDAR1 (1:100, Abcam) and rabbit poly-
clonal anti-DAP Kinase 1 (1:100, Sigma). Sections were
counterstained with Carazzi’s hematoxylin. Negative con-
trols included incubation with a non-specific immuno-
globulin of the same isotype as the primary antibody.
These sections were mounted in 90% glycerol/PBS and
examined in a blinded manner.Additional files
Additional file 1: Table S1. Proteomic and bioinformatic analysis of the
AKI dataset. Data entries were matched to various databases by accession
numbers such as SwissProt, UniProt, EnsEMBL, TrEMBL, PIR, Unigene,
Entrez (GI), IPI and NCBI-GeneIndex. Raw data from the six control and six
AKI samples, as measured by LC-MS, and derived values such as fold
changes and p-values are included.
Additional file 2: This file contains in-depth methods and results
used to generate the molecular pathway map. It also contains the
results of GO, interactome and KEGG pathway mapping analysis, as well
as the original assembly of pathway cascades used to establish the
global pathway shown in Additional file 3: Figure S1.
Additional file 3: Figure S1. Pathway map in AKI. Molecules implicated
in AKI were mapped onto pathways based on prior knowledge of signalling
cascades as well as merged de-novo pathways. Fold changes of individual
proteins range from green (down-regulation) to white (unchanged) to red
(up-regulation). Grey denotes proteins and metabolites without fold-change
information. ROS are highlighted with a green surrounding box. The legend
is included in the top-left corner.
Additional file 4: Table S2. Reported therapeutic agents employed in
acute kidney injury models. Abbreviated names are indicated in round
brackets, and gene names in square brackets.
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